Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Xencor, Inc. XNCR
$26.53
-$0.17 (-0.64%)
На 18:00, 12 мая 2023
+111.08%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1615352250.00000000
-
week52high
38.20
-
week52low
19.36
-
Revenue
164579000
-
P/E TTM
-26
-
Beta
0.79342500
-
EPS
-0.95000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 20:00
Описание компании
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 23 мая 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 24 февр 2022 г. |
| BMO Capital | Outperform | 11 февр 2022 г. | |
| HC Wainwright & Co. | Buy | 15 дек 2021 г. | |
| SVB Leerink | Outperform | Outperform | 05 авг 2021 г. |
| JP Morgan | Overweight | 21 сент 2022 г. | |
| Raymond James | Strong Buy | Outperform | 13 окт 2022 г. |
| RBC Capital | Outperform | Outperform | 08 ноя 2022 г. |
| Cowen & Co. | Outperform | 06 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Yang Allen | D | 63521 | 3737 | 19 дек 2022 г. |
| Valente Nancy | A | 35282 | 35282 | 08 сент 2022 г. |
| GUSTAFSON KURT A | A | 21412 | 21412 | 23 июн 2022 г. |
| Feigal Ellen | A | 21412 | 21412 | 23 июн 2022 г. |
| Montgomery Alan Bruce | A | 21412 | 21412 | 23 июн 2022 г. |
| RANIERI RICHARD J | A | 21412 | 21412 | 23 июн 2022 г. |
| Hata Yujiro S | A | 21412 | 21412 | 23 июн 2022 г. |
| ROSA-BJORKESON DAGMAR | A | 21412 | 21412 | 23 июн 2022 г. |
| GORMAN KEVIN CHARLES | A | 21412 | 21412 | 23 июн 2022 г. |
| Dahiyat Bassil I | D | 207815 | 2494 | 09 мар 2022 г. |
Новостная лента
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
08 мая 2023 г. в 19:03
Xencor (XNCR) came out with a quarterly loss of $1.02 per share versus the Zacks Consensus Estimate of a loss of $0.75. This compares to earnings of $0.39 per share a year ago.
7 Biotech Stocks to Buy for 100% Returns
InvestorPlace
09 апр 2023 г. в 13:19
Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.
Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023
Business Wire
14 мар 2023 г. в 16:31
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
Strength Seen in Xencor (XNCR): Can Its 5.3% Jump Turn into More Strength?
Zacks Investment Research
14 мар 2023 г. в 04:35
Xencor (XNCR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Xencor, Inc. (XNCR) Q4 2022 Earnings Call Transcript
Seeking Alpha
23 февр 2023 г. в 23:11
Xencor, Inc. (NASDAQ:XNCR ) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and IR Bassil Dahiyat - President and CEO Allen Yang - Chief Medical Officer John Kuch - CFO John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Edward Tenthoff - Piper Sandler Dane Leone - Raymond James Etzer Darout - BMO Capital Markets David Dai - SMBC Charles Zhu - Guggenheim Partners William Maughan - Canaccord Genuity Michael King - EF Hutton Brian Cheng - JPMorgan Operator Good afternoon, thank you for standing by. And welcome to the Xencor's Fourth Quarter and Year End 2022 Conference Call.